ORGANOIDS

CancerTools.org: The home for cancer research tools

antibodies_stock

PATIENT-DERIVED TUMOUR ORGANOIDS

Organoids are unique self-organising 3D microscopic structures derived from cells that represent a physiologically relevant in vitro model systems as they preserve the genomic, physiological characteristics and multicellularity of the equivalent in vivo tissue

1
  • Available cancer patient-derived organoids (PDOs) are 3D in vitro multicellular models established from a range of human tumour tissues

  • Represent a novel in vitro platform for basic biological research and potential applications in drug testing and molecular medicine

  • Use in various applications can complement existing experimental models
2
  • Prof. Motoki Takagi and his group from Fukushima Medical University (FMU) have used an independently developed method to establish F-PDOs

  • Recapitulate characteristics of in vivo tumours

  • Employed protocol does not involve enzyme treatment of the clinical material or use of extracellular matrix – the F-PDOs are cultured in suspension
3
  • Extensively characterised

  • Comprehensive gene expression, whole-exome sequencing and morphological analyses confirm the F-PDOs retain parental tissue characteristics for extended period of time in culture and after cryopreservation

  • Can be employed prior to using high-cost and time-consuming in vivo models such as patient derived xenografts (PDXs)

Organoid CTA Image

RLUN21_herceptin only_3h_10bai - with text-2

Key Features

  • Preserve parental tissue genetic profile and morphology: various characterisation tests confirm F-PDOs retain parental tissue genetic profile and morphology

  • Amenable to extended culture duration: genetically and phenotypically stable for 6 -12 months in culture and after cryopreservation

  • Suspension culture: no extracellular matrix required

  • In  vivo tumorigenesis: suitable for PDX mouse development - gene expression profiles of the xenografts are similar to those of their source F-PDOs and tissues 

  • Suitable for various assays: F-PDOs can be used to establish high-throughput assays to evaluate anticancer agents and antibodies

  • Well-characterized with annotation data: the organoids have been characterised using comprehensive gene expression, whole-exome sequencing and morphological analyses

Applications

  • Disease modelling 

  • Anticancer agents discovery and development

  • Immuno-oncology assays

  • Compounds’ safety and toxicity testing

HubSpot Video

Explore the organoids currently available by cancer type:

Bile duct cancer organoids

Breast cancer organoids

Cervical cancer organoids

Colorectal cancer organoids

Esophageal cancer organoids

Fallopian tube cancer organoids

Gastric cancer organoids

Kidney cancer organoids